Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Hutchison Medipharma Limited.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
367actual
Sites
90
Countries
Brazil, Canada, Chile +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-01-09 | actual | When the study began enrolling |
| Primary completion | 2024-08-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2018-12-19 | actual | When this record first appeared on the registry |
| Results posted | 2026-02-10 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-04-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Carcinoma
Interventions
- Drug: osimertinib
- Drug: savolitinib
- Drug: placebo
Primary outcomes
what the primary-completion date above is the date OFObjective Response Rate (ORR) by Investigator Assessment; Target Population Analysis Set
measured Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progressionuntil the end of the study, or an approximate maximum of 5.6 years.
Objective Response Rate (ORR) by Investigator Assessment; 300 mg QD Safety Analysis Set
measured Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progression until the end of the study, or an approximate maximum of 5.6 years.
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-05-24 · 6.2 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-07-03 · 2.3 MB · SAP_001.pdf
Publications
- PMID 42460617 — linked by the registry
- PMID 41308232 — linked by the registry
- PMID 32027845 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed